Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
5g |
|
||
Other Sizes |
|
ln Vitro |
The poorly differentiated human gastric cancer cell line MKN45 exhibits a considerable change in proliferation rate when exposed to furosemide (500 µM) over 72-96 hours. On the other hand, MKN28 cells—a cell line of human gastric adenocarcinoma that is moderately differentiated—were unaffected. Compared to MKN28 cells, MKN45 cells develop at a faster pace [4]. In healthy people's erythrocytes, furosemide (10 µM, 30 µM, and 100 µM; 45 min exposure) dramatically lowers [Ca(2+)](i) and cation channel activity. Similar effects were seen by tert-butyl hydroperoxide on non-selective cation channel activity, [Ca(2+)](i), and cell membrane disruption; however, furosemide considerably reduced these effects as well [5].
|
---|---|
ln Vivo |
To create a deaf mouse model, kanamycin (KM) (1000 mg/kg) and furosemide (ip; 100 mg/kg; single dose) were injected into C57BL/6 mice. On days 1, 2, and 3, following injection, hearing loss and cochlear hair cell destruction were measured, accordingly. Day 3 of the animals showed abnormal OHC (outer hair cells) morphology of the top, middle, and bottom turns, and hearing had already severely declined since day 2 (day 1 group) [3].
|
References |
[1]. C M Gillen, et al. Molecular cloning and functional expression of the K-Cl cotransporter from rabbit, rat, and human. A new member of the cation-chloride cotransporter family. J Biol Chem. 1996 Jul 5;271(27):16237-44.
[2]. S A Thompson, et al. Residues in transmembrane domains I and II determine gamma-aminobutyric acid type AA receptor subtype-selective antagonism by Furosemide sodium. Mol Pharmacol. 1999 Jun;55(6):993-9. [3]. Shin Hye Kim, et al. Novel Peptide Vaccine GV1001 Rescues Hearing in Kanamycin/Furosemide sodium-Treated Mice. Front Cell Neurosci. 2018 Jan 19;12:3. [4]. Atsushi Shiozaki , et al. Furosemide sodium, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state. J Physiol Sci. 2006 Dec;56(6):401-6. [5]. Yuliya V Kucherenko, et al.Inhibitory effect of Furosemide sodium on non-selective voltage-independent cation channels in human erythrocytes.Cell Physiol Biochem. 2012;30(4):863-75. |
Molecular Formula |
C12H11CLN2O5S
|
---|---|
Molecular Weight |
330.74
|
Exact Mass |
330.00772
|
Elemental Analysis |
C, 43.58; H, 3.35; Cl, 10.72; N, 8.47; O, 24.19; S, 9.69
|
CAS # |
54-31-9
|
Related CAS # |
Furosemide sodium;41733-55-5;Furosemide-d5;1189482-35-6
|
Appearance |
White to light yellow crystalline powder.
|
SMILES |
ClC1C([H])=C(C(C(=O)O[H])=C([H])C=1S(N([H])[H])(=O)=O)N([H])C([H])([H])C1=C([H])C([H])=C([H])O1
|
Synonyms |
Lasix; Frusemide; Furosemide
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~302.35 mM)
H2O : ~0.1 mg/mL (~0.30 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0235 mL | 15.1176 mL | 30.2352 mL | |
5 mM | 0.6047 mL | 3.0235 mL | 6.0470 mL | |
10 mM | 0.3024 mL | 1.5118 mL | 3.0235 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.